Administration of NaHS at either the early or the advanced stage of atherosclerosis suppressed the aortic expression of CX3CL1 and CX3CR1, together with reduced plaque size and IMT thickness in the main branches of the aortic arch. The gene discussed is CX3CL1; the disease is atherosclerosis.